All Stories

  1. Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer

    Article • Nature Communications, July 2024, Springer Science + Business Media

    Dr Elizabeth L Christie

  2. Crowd-sourced benchmarking of single-sample tumor subclonal reconstruction

    Article • Nature Biotechnology, June 2024, Springer Science + Business Media

    Dr Elizabeth L Christie

  3. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

    Article • Clinical Cancer Research, June 2024, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  4. Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer

    Article • Scientific Reports, December 2023, Springer Science + Business Media

    Dr Elizabeth L Christie

  5. Convergent insulin and TGF‐β signalling drives cancer cachexia by promoting aberrant fat body ECM accumulation in a Drosophila tumour model

    Article • EMBO Reports, November 2023, Springer Science + Business Media

    Dr Elizabeth L Christie

  6. Interferon-ε is a tumour suppressor and restricts ovarian cancer

    Article • Nature, August 2023, Springer Science + Business Media

    Dr Elizabeth L Christie

  7. Convergent Insulin and TGF-β signalling drives cancer cachexia by promoting aberrant fatbody ECM accumulation in aDrosophilatumour model

    Article • June 2023, Cold Spring Harbor Laboratory Press

    Dr Elizabeth L Christie

  8. Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes

    Article • Cell Reports Medicine, June 2023, Elsevier

    Dr Elizabeth L Christie

  9. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival

    Article • BMC Cancer, May 2023, Springer Science + Business Media

    Dr Elizabeth L Christie

  10. Data from Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  11. Author Correction: The landscape of viral associations in human cancers

    Article • Nature Genetics, March 2023, Springer Science + Business Media

    Professor Daniel S. Brewer, Taobo Hu, Dr Elizabeth L Christie

  12. Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing

    Article • Nature Genetics, March 2023, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  13. Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers

    Article • Nature Genetics, March 2023, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  14. Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer

    Article • Nature Genetics, March 2023, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  15. Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition

    Article • Nature Genetics, March 2023, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  16. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

    Article • Nature Genetics, February 2023, Springer Science + Business Media

    Dr Elizabeth L Christie

  17. Author Correction: Pan-cancer analysis of whole genomes

    Article • Nature, January 2023, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  18. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models

    Article • Therapeutic Advances in Medical Oncology, January 2023, SAGE Publications

    Dr Elizabeth L Christie

  19. Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

    Article • Nature Communications, December 2022, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  20. Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower

    Article • Nature Communications, December 2022, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  21. Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours

    Article • Nature Communications, December 2022, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  22. Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer

    Article • Nature Communications, December 2022, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  23. Author Correction: Inferring structural variant cancer cell fraction

    Article • Nature Communications, December 2022, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  24. Author Correction: Integrative pathway enrichment analysis of multivariate omics data

    Article • Nature Communications, December 2022, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  25. Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes

    Article • Nature Communications, December 2022, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  26. Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig

    Article • Nature Communications, December 2022, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  27. Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations

    Article • Nature Communications, December 2022, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  28. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

    Article • Nature Genetics, December 2022, Springer Science + Business Media

    Dr Elizabeth L Christie

  29. Identification of novel therapeutic targets to overcome chemoresistance in high-grade serous ovarian cancer

    Article • European Journal of Cancer, October 2022, Elsevier

    Dr Elizabeth L Christie

  30. TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members

    Article • Journal of Clinical Oncology, June 2022, American Society of Clinical Oncology (ASCO)

    Dr Elizabeth L Christie

  31. Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer

    Article • Cancers, November 2021, MDPI AG

    Dr Elizabeth L Christie

  32. Tumor-derived MMPs regulate cachexia in a Drosophila cancer model

    Article • Developmental Cell, September 2021, Elsevier

    Dr Elizabeth L Christie

  33. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer

    Article • Nature Communications, May 2021, Springer Science + Business Media

    Dr Elizabeth L Christie

  34. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes

    Article • Cell, April 2021, Elsevier

    Dr Elizabeth L Christie

  35. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer

    Article • January 2021, Research Square

    Dr Elizabeth L Christie

  36. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer

    Article • January 2021, OAE Publishing

    Dr Elizabeth L Christie

  37. The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer

    Article • January 2021, Elsevier

    Dr Elizabeth L Christie

  38. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

    Article • Nature Communications, November 2020, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  39. Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer

    Article • Cancer Research, November 2020, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  40. Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models

    Article • Blood Advances, October 2020, American Society of Hematology

    Dr Elizabeth L Christie

  41. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

    Article • Nature Communications, September 2020, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  42. Sex differences in oncogenic mutational processes

    Article • Nature Communications, August 2020, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  43. Inferring structural variant cancer cell fraction

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  44. Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  45. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

    Article • Communications Biology, February 2020, Springer Science + Business Media

    Andrés Lanzós, Dr Elizabeth L Christie, Taobo Hu

  46. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  47. Combined burden and functional impact tests for cancer driver discovery using DriverPower

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  48. Divergent mutational processes distinguish hypoxic and normoxic tumours

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  49. Genomic footprints of activated telomere maintenance mechanisms in cancer

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  50. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  51. Integrative pathway enrichment analysis of multivariate omics data

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  52. Pathway and network analysis of more than 2500 whole cancer genomes

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  53. Pan-cancer analysis of whole genomes

    Article • Nature, February 2020, Springer Science + Business Media

    Taobo Hu, Anna Ehinger, Professor Daniel S. Brewer, Dr Elizabeth L Christie

  54. The evolutionary history of 2,658 cancers

    Article • Nature, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  55. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer

    Article • Molecular Cancer Research, August 2019, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  56. TARGETING MULTIDRUG RESISTANCE PROTEIN 1 (MDR1) POTENTIATES SMAC-MIMETIC THERAPY TO KILL LEUKEMIC STEM CELLS AND OVERCOME RESISTANCE IN ACUTE MYELOID LEUKEMIA

    Article • Experimental Hematology, August 2019, Elsevier

    Dr Elizabeth L Christie

  57. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer

    Article • Nature Communications, March 2019, Springer Science + Business Media

    Dr Elizabeth L Christie

  58. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer

    Article • Hematology/Oncology Clinics of North America, December 2018, Elsevier

    Dr Elizabeth L Christie

  59. Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma

    Article • Stem Cells, November 2018, Wiley

    Dr Elizabeth L Christie

  60. Neutral tumor evolution?

    Article • Nature Genetics, October 2018, Springer Science + Business Media

    Dr Elizabeth L Christie

  61. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

    Article • BMC Cancer, January 2018, Springer Science + Business Media

    Dr Elizabeth L Christie

  62. Acquired chemotherapy resistance in ovarian cancer

    Article • Annals of Oncology, November 2017, Oxford University Press (OUP)

    Dr Elizabeth L Christie

  63. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

    Article • Clinical Cancer Research, October 2017, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  64. EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas

    Article • Cancer Research, June 2017, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  65. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer

    Article • Journal of Clinical Oncology, April 2017, American Society of Clinical Oncology (ASCO)

    Dr Elizabeth L Christie

  66. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

    Article • November 2016, Cold Spring Harbor Laboratory Press

    Dr Elizabeth L Christie

  67. Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker

    Article • Cancer Research, October 2016, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  68. A community-based model of rapid autopsy in end-stage cancer patients

    Article • Nature Biotechnology, September 2016, Nature

    Dr Elizabeth L Christie

  69. Corrigendum: Whole–genome characterization of chemoresistant ovarian cancer

    Article • Nature, October 2015, Nature

    Dr Elizabeth L Christie

  70. Whole–genome characterization of chemoresistant ovarian cancer

    Article • Nature, May 2015, Nature

    Dr Elizabeth L Christie

  71. LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

    Article • Cancer Research, August 2012, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  72. Abnormal Nuclear Pore Formation Triggers Apoptosis in the Intestinal Epithelium of elys-Deficient Zebrafish

    Article • Gastroenterology, March 2009, Elsevier

    Dr Elizabeth L Christie

  73. Determination of mRNA and Protein Expression Patterns in Zebrafish

    Article • January 2008, Springer Science + Business Media

    Dr Elizabeth L Christie